Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ferenc Nagy

Showing results (231-240 of 252) with videos related to

Pageof 26
Sort By:
Orvosi Hetilap|April 24, 2016
[Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study]Mariann Rutka, Anita Bálint, Klaudia Farkas, et al.
Ideggyogyaszati Szemle|June 30, 2015
[VALIDATION OF THE HUNGARIAN MDS-UPDRS: WHY DO WE NEED A NEW PARKINSON SCALE?]Krisztina Horvath, Aschermann Zsuzsanna, Péter Acs, et al.
Scandinavian Journal of Gastroenterology|November 12, 2014
Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapyAnita Bálint, Klaudia Farkas, Pallagi-Kunstár Éva, et al.
Parkinson'S Disease|December 16, 2014
Is the MDS-UPDRS a Good Screening Tool for Detecting Sleep Problems and Daytime Sleepiness in Parkinson's Disease?Krisztina Horváth, Zsuzsanna Aschermann, Péter Acs, et al.
Ideggyogyaszati Szemle|July 18, 2015
[VALIDATION OF THE HUNGARIAN UNIFIED DYSKINESIA RATING SCALE]Krisztina Horváth, Zsuzsanna Aschermann, Péter Ács, et al.
Biomedicines|May 28, 2022
PET/MRI in the Presurgical Evaluation of Patients with Epilepsy: A Concordance AnalysisKatalin Borbély, Miklós Emri, István Kenessey, et al.
Journal of Crohn'S & Colitis|December 22, 2010
A study in three European IBD cohorts confirms that the ATG16L1 c.898A>G (p.Thr300Ala) variant is a susceptibility factor for Crohn's diseaseCarsten Büning, Tahir Durmus, Tamas Molnar, et al.
Expert Opinion on Biological Therapy|November 30, 2019
Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort studyRenáta Bor, Anna Fábián, Mária Matuz, et al.
Journal of Crohn'S & Colitis|April 24, 2016
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative ColitisKlaudia Farkas, Mariann Rutka, Petra A Golovics, et al.
Expert Opinion on Biological Therapy|October 3, 2018
Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohortAnita Bálint, Mariann Rutka, Martin Kolar, et al.
Pageof 26

Showing results (231-240 of 252) with videos related to

Sort By:
Pageof 26
Orvosi Hetilap|April 24, 2016
[Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study]Mariann Rutka, Anita Bálint, Klaudia Farkas, et al.
Ideggyogyaszati Szemle|June 30, 2015
[VALIDATION OF THE HUNGARIAN MDS-UPDRS: WHY DO WE NEED A NEW PARKINSON SCALE?]Krisztina Horvath, Aschermann Zsuzsanna, Péter Acs, et al.
Scandinavian Journal of Gastroenterology|November 12, 2014
Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapyAnita Bálint, Klaudia Farkas, Pallagi-Kunstár Éva, et al.
Parkinson'S Disease|December 16, 2014
Is the MDS-UPDRS a Good Screening Tool for Detecting Sleep Problems and Daytime Sleepiness in Parkinson's Disease?Krisztina Horváth, Zsuzsanna Aschermann, Péter Acs, et al.
Ideggyogyaszati Szemle|July 18, 2015
[VALIDATION OF THE HUNGARIAN UNIFIED DYSKINESIA RATING SCALE]Krisztina Horváth, Zsuzsanna Aschermann, Péter Ács, et al.
Biomedicines|May 28, 2022
PET/MRI in the Presurgical Evaluation of Patients with Epilepsy: A Concordance AnalysisKatalin Borbély, Miklós Emri, István Kenessey, et al.
Journal of Crohn'S & Colitis|December 22, 2010
A study in three European IBD cohorts confirms that the ATG16L1 c.898A>G (p.Thr300Ala) variant is a susceptibility factor for Crohn's diseaseCarsten Büning, Tahir Durmus, Tamas Molnar, et al.
Expert Opinion on Biological Therapy|November 30, 2019
Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort studyRenáta Bor, Anna Fábián, Mária Matuz, et al.
Journal of Crohn'S & Colitis|April 24, 2016
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative ColitisKlaudia Farkas, Mariann Rutka, Petra A Golovics, et al.
Expert Opinion on Biological Therapy|October 3, 2018
Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohortAnita Bálint, Mariann Rutka, Martin Kolar, et al.
Pageof 26